Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.4 CHF | -0.50% | -0.37% | -4.05% |
Apr. 04 | Global markets live: Novo Nordisk, Ocado, Walt Disney, Apple, Tesla... | |
Apr. 04 | Medartis Issues CFH116 Million Convertible Bonds | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 114.99 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.59 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.05% | 1.2B | B- | ||
+9.07% | 124B | A- | ||
-7.78% | 10.74B | A- | ||
+2.17% | 8.93B | C | ||
+23.48% | 7.61B | C | ||
+32.13% | 5.27B | B+ | ||
+7.84% | 3.42B | C- | ||
-6.94% | 2.86B | B- | ||
-5.07% | 2.23B | - | - | |
-4.22% | 2.13B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MED Stock
- Ratings Medartis Holding AG